Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.16%
#3 Velvet Velvet +44.46%
#4 Akedo Akedo +40.57%
#5 Black Phoenix Black Phoenix +33.98%
#6 Cross Cross +24.15%
#7 Cap Cap +20.35%
#8 DoubleZero DoubleZero +14.60%
#9 Tutorial Tutorial +11.59%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.77%
Coin of the day
Islamic Coin Islamic Coin
Innstillinger
Språk
NORSK
Valuta
USD
Tema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Rangering i aksjer #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Aksjekurs
$0.11725176
Sist synkronisert: 2025-07-14
Markedsverdi
$481.50K
Endring (1 dag)
-0.20%
Endring (1 år)
0.00%
Land
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)

Kategori

Healthcare
P/E-forhold for PHAXIAM Therapeutics S.A. (PHXM)
P/E-forhold per August 2026 TTM: -0.02
Ifølge PHAXIAM Therapeutics S.A. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -0.02. Ved slutten av 2022 hadde selskapet en P/E på -49.90.
P/E-forholdshistorikk for PHAXIAM Therapeutics S.A. fra 2016 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) -0.02 -97.64%
2023 -0.85 -98.30%
2022 -49.90 5,245.05%
2021 -0.93 -47.66%
2020 -1.78 -7.01%
2019 -1.92 -34.61%
2018 -2.93 -53.24%
2017 -6.27 25.89%
2016 -4.98 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -139,643.28%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -155,046.27%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -96,113.43%
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.